Indications |
Oral HIV infection Adult: Lopinavir 400 mg (with ritonavir 100 mg) bid. In treatment naive patients: 800 mg (with ritonavir 200mg) once daily may be used. When taken with amprenavir, efavirenz, nevirapine or nelfinavir in treatment experienced patients, dose increases to 600 mg (with ritonavir 150 mg) bid (tablets) or 533 mg (with ritonavir 133 mg) bid (capsules and oral solution) may be required. Child: >2 yr: Lopinavir 230 mg (with ritonavir 57.5 mg) /m2 bid. When taken with amprenavir, efavirenz, nevirapine or nelfinavir, dose may be increased to 300 mg (with ritonavir 75 mg) /m2 bid if required. Max dose 400 mg bid. Oral HIV postexposure prophylaxis Adult: 400 mg (with ritonavir 100 mg) bid, to be used with at least 2 other antiretrovirals. Treatment should be initiated as soon as possible (preferably within 72 hr) and continued for 28 days. |
Contraindications |
Hypersensitivity; renal or hepatic failure; lactation; Concomitant use of drugs highly dependant on CYP3A for clearance and associated with serious toxicity. |
Warnings / Precautions |
DM, haemophilia A and B, hepatitis; renal impairment; hyperlipidaemia or hypercholesterolaemia, monitor for signs of lipodystrophy. Always use with other antiretroviral agents in HIV treatment. Capsules and oral solution not interchangeable on a mg-per-mg basis. Pregnancy (oral solution CI). Monitor for propylene glycol-associated adverse effect when oral solution is administered. |
Adverse Reactions |
Diarrhoea, abdominal pain, asthenia, headache, dyspepsia, vomiting, myalgia, bronchitis, hypertension, palpitation, thrombophlebitis, vasculitis, agitation, anxiety, ataxia, hypertonia, confusion, depression, dyskinesia, peripheral neuritis; Cushing's syndrome; hypothyroidism, sexual dysfunction, lactic acidosis, arthralgia, abnormal vision, otitis media, tinnitus, acne, alopoecia, dry skin, skin discoloration, nail disorders, sweating. Potentially Fatal: Pancreatitis. |
Overdose Reactions |
Treat symptomatically with general supportive measures. Activated charcoal may aid in removal of unabsorbed drug. |
Drug Interactions |
Most interactions reported with lopinavir are due to its combination with the potent inhibitor of CYP3A4 ritonavir. Lopinavir levels may be decreased by CYP3A4 inducers such as efavirenz, nevirapine, amprenavir, nelfinavir, rifampicin, phenytoin. Lopinavir level are increased by CYP3A4 inhibitors such as valproate and rifabutin. Potentially Fatal: Severe myelosuppression reported with paclitaxel. See Below for More lopinavir Drug Interactions |
Mechanism of Actions |
Lopinavir is an antiretroviral agent which inhibits HIV protease, causing the enzyme incapable of processing the polyprotein precursor. This leads to the production of non-infectious and immature HIV particles. Lopinavir is used in combination with ritonavir, which increases the bioavailability to therapeutic levels. Absorption: Absorbed from the GI tract. Tablet formulation unaffected by food but liquid capsules and oral liquid have improved bioavailability when taken with food. Distribution: Approx 98-99% plasma bound. Metabolism: Metabolised hepatically by isoenzyme CYP3A. Excretion: Eliminated via urine (10%) and faeces (83%). |
Administration |
Should be taken with food. |
Storage Conditions |
Oral: Tablets: Store at 20-25°C in original container. Oral liquid and capsules: store at 2-8°C until dispensed then at ≤25°C for up to 2 mth. |
ATC Classification |
J05AE06 - lopinavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections. |
Storage |
Oral: Tablets: Store at 20-25°C in original container. Oral liquid and capsules: store at 2-8°C until dispensed then at ≤25°C for up to 2 mth. |
Available As |
|
Lopinavir
Post Review about Lopinavir Click here to cancel reply.
Lopinavir Containing Brands
Lopinavir is used in following diseases
Drug - Drug Interactions of Lopinavir
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.